Pharmacists would be aware of the down scheduling of some nicotine vaping or e-cigarette products to S3 from 1 October 2024. PDL has recently provided
NSW pharmacists The oral contraceptive resupply component of the NSW Pharmacy Trial ceased on 27 September 2024. From 28 September 2024, NSW pharmacists holding general
The Pharmacy Stakeholder Forum is a joint initiative between the Pharmacy Council of NSW, NSW Ministry of Health and other pharmacy organisations representing most NSW
Pharmacies in NSW providing a UTI service must meet the requirements of the Authority. Under this authority, pharmacies are required to maintain an up-to-date UTI
Information from the Pharmaceutical Services Unit (PSU) The PDL Professional Officers often receive enquiries relating to the validity of psychostimulant prescriptions written for NSW patients.
The UTI component of the NSW Pharmacy Trial ceased on 31 May 2024. From 1 June 2024, NSW pharmacists holding general registration, who have completed
Pharmacists have admirably navigated the changes to the provision of the Opioid Therapy Program (OTP) in 2023, overcoming numerous challenges whilst maintaining uninterrupted service to
Psychostimulant changes The PDL Professional Officers would like to bring to the attention of NSW pharmacists some recent regulatory changes regarding the requirements to prescribe
Pharmacists have limited time left to register their interest in their pharmacy taking part in the NSW Pharmacy Trial, with the expression of interest process
The NSW Government-sponsored Pharmacy Trial for the extended supply of oral contraceptive pills (OCPs) by community pharmacists commenced on 27 September 2023. The trial aims
Pharmaceutical Defence Limited (PDL) acknowledges the Traditional Owners of Country throughout Australia and their continuing connection to land, waters and community. We pay our respects to the people, the cultures and the Elders past and present.